TABLE 1.
Clinical outcomes of DPP4 inhibitors in COVID-19 patients with T2DM.
| Reference | Research type | Country | Sample size (users/non-users) | Intensive care or mortality (users/non-users) |
|---|---|---|---|---|
| Solerte et al. (2020a) | Retrospective | Italy | 338 (169/169) | 18%/37% |
| J. H. Zhou et al., 2020b | Retrospective | China | 444 (111/333) | 1.8%/3.3% |
| Rhee et al. (2021) | HIRA database | Korea | 832 (263/569) | 3.4%/4.4% |
| NHIS database | Korea | 704 (175/529) | 8%/11.5% | |
| Y. Chen et al., 2020a | Retrospective | China | 120 (20/100) | 25%/14% |
| Mirani et al. (2020) | Retrospective | Italy | 90 (11/79) | 9.1%/46.8% |
| Wargny et al. (2021) | Retrospective | France | 2794 (615/2179) | 18.3%/21.3% |
| Fadini et al. (2020) | Retrospective | Italy | 85 (9/76) | 11.1%/13.9% |
| Noh et al. (2021) | Cohort | — | 586 (453/133) | 10.4%/16.5% |
| Pérez-Belmonte et al. (2020) | Retrospective | Spain | 1589 (180/1409) | 41.7%/31.2% |
| Roussel et al. (2021) | Cohort | France | 2449 (596/1853) | 9.7%/11.7% |
| Silverii et al. (2021) | Retrospective | Italy | 159 (13/146) | 38.5%/37.0% |
| Israelsen et al. (2021) | Retrospective | Denmark | 928 (284/644) | 10.6%/3.3% |
| Cariou et al. (2020) | Retrospective | France | 1317 (285/1032) | 9.5%/10.9% |
HIRA, health insurance review and assessment service; NHIS: national health insurance service.